Abstract. Adiponectin, secreted specifically from adipocytes, is thought to play a key role in the metabolic syndrome. Plasma adiponectin concentrations were studied in 36 typical nonalcoholic fatty liver (NAFL) women which is commonly associated with the metabolic syndrome. They were diagnosed as NAFL by ultrasound brightness, slightly elevated serum ALT levels and the exclusion of history of alcohol abuse and other known liver diseases. Compared with 64 control women, NAFL had a significant increase in the variables of the metabolic syndrome, other hepatic enzymes and leptin levels, while a reduction in AST/ALT ratio and adiponectin before (mean ± SE: 7.2 ± 0.5 vs 9.0 ± 0.4 mg/ml, p<0.005) and after adjustment for body fat mass (0.24 ± 0.02 vs 0.34 ± 0.02, p<0.0001), atherogenic Index [(total cholesterol -HDLC)/ HDLC: 3.2 ± 0.3 vs 4.6 ± 0.3, p<0.005] or calculated insulin resistance (HOMA-R) (6.6 ± 1.9 vs 8.6 ± 0.9, p<0.005). BMI and amylase were positive, and adiponectin/BMI was negative significant independent determinants of ALT value in multiple regression model. In conclusion, while hypoadiponectinemia was observed in NAFL, hypoadiponectinemia provides the possibility of fat accumulation in the liver.
ADIPOSE tissue is now thought to be one of the endocrine organs in human, as it synthesizes and secretes several cytokines, such as tumor necrosis factor (TNF)-a, interleukin 6, plasminogen activator inhibitor-1, leptin and adiponectin, the latter being one of the most abundant adipose tissue-specific adipocytokines [1] . Besides inhibiting inflammatory pathways [2] [3] [4] , recombinant adiponectin increases insulin sensitivity and improves glucose tolerance in animal models [5] [6] [7] . Adiponectin expression and/or secretion is increased by insulin like growth factor-1, ionomycin and activators of peroxisome proliferator-activated receptor (PPAR)-g, and decreased by TNF-a, glucocorticoids, b-adrenergic agonists and cAMP [7, 8] . In humans, decreased plasma adiponectin levels have been found in patients with obesity [9, 10] , type 2 diabetes [11] , insulin resistance [12, 13] , dyslipidemia [14] , coronary artery disease [8, 11] and low-grade C-reactive protein (CRP) elevation [15, 16] . Genomic wide scan studies [17, 18] have revealed linkage of the metabolic syndrome and type 2 diabetes to a region on chromosome 3q27, where the gene encoding adiponectin is located [19] . Furthermore, there is increasing evidence that genetic variants in the adiponectin gene itself may be associated with hypoadiponectinemia, insulin resistance and type 2 diabetes [20] [21] [22] . Thus, these suggest the possibility that this protein is playing a key role in the metabolic syndrome [13, 15] .
Nonalcoholic fatty liver (NAFL) is most commonly associated with the metabolic syndrome, i.e., obesity, dyslipidemia and insulin resistance [23, 24] . Recently, adiponectin receptor was reported to be expressed in skeletal muscle as Adipo R1 and liver as Adipo R2 [25] . The current study tests the hypothesis that there is an association between NAFL and adiponectin which not only enhances the combustion of fatty-acid in skeletal muscle, and thereby reduces serum triglyceride (TG) and free fatty-acid (FFA) levels, but also increases hepatic fatty-acid oxidation through activation of AMP kinase and PPAR-a [7, 8] . Because sex differ-ences have been reported in plasma adiponectin [8, 9] , leptin [26, 27] , TG, high-density lipoprotein cholesterol (HDLC), g-glutamyltranspeptidase (g-GTP), cholinesterase (Cho.E) and body fat mass (BFM, %), the author chose to study women only.
Subjects and Methods

Subjects and measurements
One hundred Japanese women aged 25 to 79 years old (mean ± SE, 54.8 ± 1.0 yrs) excluding those with birth control pill use, postmenopausal hormone replacement therapy, receiving iron supplementation, avitaminosis, diabetes mellitus, renal failure, untreated endocrine diseases, history of alcohol abuse (daily alcohol intake >20 g), pancreatitis, other known liver diseases, malignancy or pregnancy, were included in this study. All cases received an ultrasound scan of the liver. Ultrasound studies were carried out by the experienced operators who were blinded to laboratory values. Thirty-six women aged 55.3 ± 2.1 years were diagnosed as NAFL by marked ultrasound brightness and the slightly elevated serum alanine aminotransferase (ALT) levels (range 30-141, 45 ± 4 U/l). Sixtyfour control women aged 54.5 ± 1.3 years were not observed to have the ultrasound brightness and the elevation of serum ALT levels (7-20, 14 ± 1 U/l). Participants were recruited and examined between March 1999 and October 2000 in principle, and were in follicular phase among menstruating women. Insulin resistance was calculated as homeostasis model assessment-ratio [HOMA-R: fasting plasma glucose (mg/dl) × fasting insulin (mU/ml) ÷ 405] and atherogenic index (AI) was (total cholesterol -HDLC)/HDLC [10, 14] . Percent BFM was determined by bioelectrical impedance analysis [10, 14] . All subjects reported that their body weight had been stable (±2 kg) for at least 3 months before the study, and they provided informed consent.
Plasma adiponectin, leptin and various parameters were determined as previously reported [10, 14] and several hepatopancreatic enzymes were measured with an autoanalyzer (TBA-200FR, Toshiba, Tokyo).
Statistical analyses
The study assessed associations among variables in all women with use of Pearson's correlation coefficient. Plasma adiponectin, leptin, high sensitive-CRP, TG, AI, insulin, HOMA-ratio(R), aspartate aminotransferase (AST), ALT, alkaline phosphatase (Al-P) and g GTP were log-transformed to correct their skewed distributions. Adiponectin/BMI, BFM, AI or HOMA-R were calculated as the most easily comprehensible markers for the adjustment. The differences between NAFL and control groups were tested using unpaired t test. Multiple regression models fitted for serum ALT, amylase or adiponectin/BMI as a dependent variable, including variables of interest at the same time as independent variables to demonstrate the relative contribution of each of these variables to the outcome variable. The following independent variables were considered for the model: age, diastolic BP, BMI, creatinine, log-CRP, TG, HOMA-R, and/or ALT, and/ or amylase, and/or adiponectin/BMI. All data are expressed as the mean ± SE. A p-value less than 0.05 was considered to be statistically significant.
Results
Serum ALT was correlated not only with other hepatic enzymes but also with variables of the metabolic syndrome such as BP, BMI, BFM, serum TG, insulin, HOMA-R and leptin (Table 1) . Serum ALT was negatively associated with adiponectin before (r = -0.346, p<0.001) and after adjustment for BFM (r = -0.467, p<0.0001), AI (r = -0.341, p<0.001) or HOMA-R (r = -0.399, p<0.0001) ( Table 1) . Moreover, serum amylase was positively associated with age, serum hepatic enzymes, creatinine, uric acid, total cholesterol, HDLC and adiponectin, and negatively with WBC levels.
Compared with control group, NAFL women had a significant increase in other hepatic enzymes, BMI, BFM, serum TG, insulin, HOMA-R and leptin levels ( Table 2) , while showing a reduction in AST/ALT ratio and adiponectin before (7.2 ± 0.5 vs 9.0 ± 0.4 mg/ml, p<0.005) and after adjustment for BFM (0.24 ± 0.02 vs 0.34 ± 0.02, p<0.0001), AI (3.2 ± 0.3 vs 4.6 ± 0.3, p<0.005) or HOMA-R (6.6 ± 1.9 vs 8.6 ± 0.9, p<0.005) (Fig. 1) .
In multiple regression analysis model (Table 3) , BMI and amylase were positive, and adiponectin/BMI value was a negative significant independent determinant of serum ALT value. Amylase was positive, and ALT was a negative significant independent determinant of adiponectin/BMI value. Moreover, serum ALT and adiponectin/BMI value were positive, and CRP was a negative significant independent determinant of serum amylase value (Table 3) . Datal are presented as mean ± SE. #: log-transformed statistics. 
Discussion
The present study confirmed the association between NAFL and the variables of the metabolic syndrome [23, 24] . In addition to confirming the association between hepatopancreatic function and adiponectin [28] , the study found that plasma adiponectin concentrations were decreased in typical NAFL cases, although the author did not perform the liver biopsy in this study. Low plasma adiponectin level was closely associated with NAFL independent of BFM, HOMA-R or AI. The pathogenesis of NAFL is proposed to be an aberration in fatty-acid and triglyceride metabolism that leads to hepatic triglyceride accumulation [23, 29] . The diagnosis of NAFL is based on exclusion of known etiologic factors responsible for liver disease (viral, genetic, autoimmune) and on ultrasound examinations. In NAFL, levels of serum AST and ALT are usually elevated, and AST/ALT ratio decreased. The initial stage subjects of the metabolic syndrome frequently have increased serum TG levels, hypertension, insulin resistance and splanchnic fat distribution in the absence of overt obesity [23, 24] . Insulin resistance also involves lipid metabolism. Hypertriglyceridemia was shown to be associated with NAFL together with increased FFA levels [23, 24] . Accumulation of fat in the liver can occur because of increased delivery of FFA to the liver, increased synthesis of fatty-acid in the liver, decreased b-oxidation of FFA, and decreased synthesis or secretion of very low-density lipoprotein cholesterol [29, 30] . Hypoadiponectinemia not only accompanies elevated serum TG and FFA levels due to the reduction of fatty-acid combustion in skeletal muscle [5, 6] , but also decreases hepatic fatty-acid oxidation through activation of AMP kinase and PPAR-a, and increases the activities of fatty-acid synthesis enzymes [7, 8] . These fat accumulation processes may induce fatty liver. Moreover, Yamauchi et al. [25] , reported the cloning of complementary DNAs encoding adiponectin receptors 1 and 2 (Adipo R1 and Adipo R2). Adipo R1 is abundantly expressed in skeletal muscle, whereas Adipo R2 is predominantly expressed in the liver. Thus, it is possible that a low production of adiponectin from adipose tissue may be involved in NAFL through the accumulation of lipids. However, Tsuchida et al. [31] reported that the expression of Adipo R1/R2 appeared to be inversely regulated by insulin in physiological and pathophysiological states in hyperinsulinemic models and was correlated with adiponectin sensitivity. It is possible that decreased expression of adiponectin receptor is also involved in the decreased adiponectin action in the liver in NAFL subjects. TNF-a has been linked with the pathology of alcoholic liver dysfunction, fatty liver, nonalcoholic steatohepatitis and the progression of hepatic fibrogenesis [29, 30] . Since adiponectin is known to suppress TNF-a action [3, 4, 7] , adiponectin may exert a hepatic protective effect. Recently, Xu et al. [32] reported the decreased circulating adiponectin levels in mice with the chronic consumption of high-fat ethanol-containing food, and that recombinant adiponectin administration into these mice alleviated the hepatomegaly, steatosis and elevated serum ALT levels. Kamada et al. [33] also reported a preventive effect of adiponectin on hepatic fibrosis in rodent. The possible relevance of decreased adiponectin in the pathogenesis of nonalcoholic fatty liver has potential therapeutic implications that need to be tested in clinical studies.
Recently, Kharroubi et al. [34] reported the marked expression of adiponectin receptors Adipo R1 and Adipo R2 in human and rat pancreatic b-cells, at levels similar to liver and greater than muscle. Rakatzi et al. [35] reported that globular domain of adiponectin has an anti-apoptotic function without modulating nuclear factor-kB activation in the pancreatic b-cell line. Although the present association between plasma adiponectin and amylase levels may support the relation of adipose derived protein, adiponectin with pancreatic function, amylase isozymes should be determined in future trials.
In conclusion, while the present study observed hypoadiponectinemia in nonalcoholic fatty liver, hypoadiponectinemia provides the possibility of fat accumulation in the liver.
